title: [Balloon occluded arterial infusion (BOAI) therapy in patients with progressive cervical carcinoma].
abstract: Ten patients with progressive cervical carcinoma were treated with intra-arterial infusion by BOAI (balloon occluded arterial infusion) in order to secure high concentrations of anti-tumor agents. This study included 9 cases (2 stage IIb, 5 stage IIIb, and 2 stage IV) with squamous cell carcinoma and 1 case (stage IIIb) with adenocarcinoma. Cis-platin (CCDP) 100 mg/body and bleomycin (BLM) 20-30 mg/body and and/or aclacinomycin (ACM) 30-40 mg/body were infused after the bilateral internal iliac arteries were occluded. 1. The serum concentration of free-Pt reached its maximum 15-30 min after BOAI therapy and returned to an undetectable level in 3 hours. 2. The free-Pt concentration following BOAI therapy was 2 to 3 times greater than those found with intravenous infusion. 3. The free-Pt concentration in internal iliac arteries was twice as great as those observed in the femoral arteries or peripheral veins. 4. The tissue concentration of Pt after BOAI was significantly (p less than 0.05) greater than those found with intra-venous infusion. 5. BOAI treatment resulted in 2 cases of partial response, 6 cases of minor response and 2 cases with no change. These results demonstrate that BOAI therapy is effective for the treatment of progressive cervical carcinoma by increasing intratumoral concentrations of the drugs.
authors: Department of Obstetrics and Gynecology, Fujita-Gakuen Health University School of Medicine, Aichi.
authors: T
authors: T
authors: Sawada
authors: T
authors: T
authors: Ebihara
authors: K
authors: K
authors: Maruyama
authors: Y
authors: Y
authors: Tateyama
authors: Y
authors: Y
authors: Yoshimura
authors: S
authors: S
authors: Kawakami
authors: M
authors: M
authors: Fukushima
mesh_terms: D015250:Aclarubicin / Q000008:administration & dosage / Q000031:analogs & derivatives; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage* / Q000627:therapeutic use; D001761:Bleomycin / Q000008:administration & dosage; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy / Q000378:metabolism / Q000628:therapy; D002404:Catheterization; D002945:Cisplatin / Q000008:administration & dosage / Q000493:pharmacokinetics; D004621:Embolization, Therapeutic / Q000379:methods; D005069:Evaluation Studies as Topic; D005260:Female; D006801:Humans; D007083:Iliac Artery; D007261:Infusions, Intra-Arterial; D007262:Infusions, Intravenous; D007263:Infusions, Parenteral; D008875:Middle Aged; D010984:Platinum / Q000097:blood / Q000493:pharmacokinetics; D012074:Remission Induction; D014018:Tissue Distribution; D002583:Uterine Cervical Neoplasms / Q000188:drug therapy / Q000378:metabolism / Q000628:therapy*
chemical_list: C011157:aclacinomycins; D001761:Bleomycin; D010984:Platinum; D015250:Aclarubicin; D002945:Cisplatin